Literature DB >> 27928076

Rapid Detection of Mycobacterium tuberculosis Strains Resistant to Isoniazid and/or Rifampicin: Standardization of Multiplex Polymerase Chain Reaction Analysis.

Jimena Collantes1,2, Francesca Barletta Solari3,2, Leen Rigouts4,5.   

Abstract

Drug susceptibility testing using molecular techniques can enhance the identification of drug-resistant Mycobacterium tuberculosis Two multiplex real-time polymerase chain reaction (qPCR) assays were developed to detect the most common resistance-associated mutations to isoniazid (katGS315T, inhA-15C → T), and rifampicin (rpoBH526Y and rpoBS531L). To assess the species specificity of the qPCR, we selected 31 nontuberculous mycobacteria (NTM) reference strains belonging to 17 species from the public collection of mycobacterial cultures (BCCM/ITM). Additionally, we tested 17 isoniazid and/or rifampicin-resistant strains with other mutations in the target genes to assess mutation specificity. The limit of detection for all the targeted mutations was 20 bacilli/reaction. Multiplex 1 showed 90%, 95%, and 100% efficiency for wild type (WT), Mut katGS315T, and Mut rpoBS531L, respectively; whereas Multiplex 2 showed 97%, 94%, and 90% efficiency for WT, Mut inhA-15, and Mut rpoBH526Y, respectively. Three of 17 strains that presented other mutations in the target genes were identified as rifampicin resistant and only 3/31 NTM showed a similar melting temperature to rpoBL531 and/or katGT315 mutants. Thus, our proposed cascade of specific tuberculosis detection followed by drug resistance testing showed sensitivities for katGS315T, rpoBS531L, rpoBH526Y, and inhA-15 detection of 100%, 100%, 100%, and 96%, respectively; and specificities of 98%, 95%, 100%, and 100, respectively. © The American Society of Tropical Medicine and Hygiene.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27928076      PMCID: PMC5154436          DOI: 10.4269/ajtmh.16-0120

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  55 in total

1.  Detection of mutations associated with isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates from Samara Region, Russian Federation.

Authors:  V Nikolayevsky; T Brown; Y Balabanova; M Ruddy; I Fedorin; F Drobniewski
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  Rapid detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method.

Authors:  Raquel Moure; Laura Muñoz; Miriam Torres; Miguel Santin; Rogelio Martín; Fernando Alcaide
Journal:  J Clin Microbiol       Date:  2010-12-29       Impact factor: 5.948

3.  Two-sided confidence intervals for the single proportion: comparison of seven methods.

Authors:  R G Newcombe
Journal:  Stat Med       Date:  1998-04-30       Impact factor: 2.373

4.  Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey.

Authors:  N Martín-Casabona; A R Bahrmand; J Bennedsen; V Ostergaard Thomsen; M Curcio; M Fauville-Dufaux; K Feldman; M Havelkova; M L Katila; K Köksalan; M F Pereira; F Rodrigues; G E Pfyffer; F Portaels; J Rosselló Urgell; S Rüsch-Gerdes; E Tortoli; V Vincent; B Watt
Journal:  Int J Tuberc Lung Dis       Date:  2004-10       Impact factor: 2.373

5.  Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in The Netherlands.

Authors:  H R van Doorn; P E W de Haas; K Kremer; C M J E Vandenbroucke-Grauls; M W Borgdorff; D van Soolingen
Journal:  Clin Microbiol Infect       Date:  2006-08       Impact factor: 8.067

6.  The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study.

Authors:  Wouter Hoefsloot; Jakko van Ingen; Claire Andrejak; Kristian Angeby; Rosine Bauriaud; Pascale Bemer; Natalie Beylis; Martin J Boeree; Juana Cacho; Violet Chihota; Erica Chimara; Gavin Churchyard; Raquel Cias; Rosa Daza; Charles L Daley; P N Richard Dekhuijzen; Diego Domingo; Francis Drobniewski; Jaime Esteban; Maryse Fauville-Dufaux; Dorte Bek Folkvardsen; Noel Gibbons; Enrique Gómez-Mampaso; Rosa Gonzalez; Harald Hoffmann; Po-Ren Hsueh; Alexander Indra; Tomasz Jagielski; Frances Jamieson; Mateja Jankovic; Eefje Jong; Joseph Keane; Wo-Jung Koh; Berit Lange; Sylvia Leao; Rita Macedo; Turid Mannsåker; Theodore K Marras; Jeannette Maugein; Heather J Milburn; Tamas Mlinkó; Nora Morcillo; Kozo Morimoto; Dimitrios Papaventsis; Elia Palenque; Mar Paez-Peña; Claudio Piersimoni; Monika Polanová; Nalin Rastogi; Elvira Richter; Maria Jesus Ruiz-Serrano; Anabela Silva; M Pedro da Silva; Hulya Simsek; Dick van Soolingen; Nora Szabó; Rachel Thomson; Teresa Tórtola Fernandez; Enrico Tortoli; Sarah E Totten; Greg Tyrrell; Tuula Vasankari; Miguel Villar; Renata Walkiewicz; Kevin L Winthrop; Dirk Wagner
Journal:  Eur Respir J       Date:  2013-04-18       Impact factor: 16.671

7.  Variations in the occurrence of specific rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolates from patients of different ethnic groups in Kuwait.

Authors:  Suhail Ahmad; Noura M Al-Mutairi; Eiman Mokaddas
Journal:  Indian J Med Res       Date:  2012-05       Impact factor: 2.375

8.  Isolation of mycobacteria from clinical samples collected in the United States from 2004 to 2011.

Authors:  Tyler C Thacker; Suelee Robbe-Austerman; Beth Harris; Mitchell Van Palmer; Wade Ray Waters
Journal:  BMC Vet Res       Date:  2013-05-08       Impact factor: 2.741

Review 9.  Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review.

Authors:  Marva Seifert; Donald Catanzaro; Antonino Catanzaro; Timothy C Rodwell
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

Review 10.  Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.

Authors:  Dick Menzies; Andrea Benedetti; Anita Paydar; Sarah Royce; Pai Madhukar; William Burman; Andrew Vernon; Christian Lienhardt
Journal:  PLoS Med       Date:  2009-09       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.